New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs

• Published in: Cellular and molecular life sciences : CMLS Vol. 61; no. 9; pp. 1042 - 1068
• Main Authors: Schally, A V, Szepeshazi, K, Nagy, A, Comaru-Schally, A M, Halmos, G
• Format: Journal Article
• Language: English
• Published: Switzerland Springer Nature B.V 01-04-2004; Birkhäuser-Verlag
• Subjects: Animals; Biomedicine and Disease: Review; Bombesin - analogs & derivatives; Bombesin - pharmacology; Colonic Neoplasms - drug therapy; Growth factors; Growth hormones; Health problems; Humans; Insulin-like growth factors; Oligopeptides - pharmacology; Pancreatic Neoplasms - drug therapy; Peptides; Somatostatin - analogs & derivatives; Somatostatin - pharmacology; Stomach Neoplasms - drug therapy
• ISSN: 1420-682X; 1420-9071
• DOI: 10.1007/s00018-004-3434-3

Cancers of the stomach, colon and exocrine pancreas are major international health problems and result in more than a million deaths worldwide each year. The therapies for these malignancies must be improved. The effects of gastrointestinal (GI) hormonal peptides and endogenous growth factors on these cancers were reviewed. Some GI peptides, including gastrin and gastrin-releasing peptide (GRP) (mammalian bombesin), appear to be involved in the growth of neoplasms of the GI tract. Certain growth factors such as insulin-like growth factor (IGF)-I, IGF-II and epidermal growth factor and their receptors that regulate cell proliferation are also implicated in the development and progression of GI cancers. Experimental investigations on gastric, colorectal and pancreatic cancers with analogs of somatostatin, antagonists of bombesin/GRP, antagonists of growth hormone-releasing hormone as well as cytotoxic peptides that can be targeted to peptide receptors on tumors were summarized. Clinical trials on peptide analogs in patients with gastric, colorectal and pancreatic cancers were reviewed and analyzed. It may be possible to develop new approaches to hormonal therapy of GI malignancies based on various peptide analogs.